Merck loses ground to SummitCompetition in the lung cancer arena has Summit Therapeutics Ivonescimab outperforming Keytruda in NSCLC. Gee.....if I was the Merck Board and I was reading all this discussion about Ruvidar (since Merck is manufacturing it) and my stock price just dropped on this news. What would I do about it?